Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What is a normal CA125 level?

T Alagoz1, R E Buller, M Berman

  • 1Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242.

Gynecologic Oncology
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of recombinant human tumor-necrosis-factor-alpha and dequalinium chloride on human ovarian-cancer cell-lines in-vitro.

International journal of oncology·2011
Same author

Recruitment strategies for cervical cancer prevention study.

Gynecologic oncology·2002
Same author

Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapy.

Cancer·2001
Same author

In vitro chemosensitivity testing and mechanisms of drug resistance.

Current oncology reports·2000
Same author

University of California, Irvine, College of Medicine.

Academic medicine : journal of the Association of American Medical Colleges·2000
Same author

Malignant germ cell tumors of the ovary.

Obstetrics and gynecology·2000
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

The standard CA125 level for monitoring ovarian cancer may be too high. This study suggests a lower normal range of 20 U/ml for patients post-gynecologic cancer surgery.

Area of Science:

  • Gynecologic Oncology
  • Clinical Chemistry
  • Biomarker Research

Background:

  • The current standard for serum CA125 levels (35 U/ml) was established using a general population, not specifically post-treatment cancer patients.
  • Accurate interpretation of CA125 is crucial for monitoring residual disease and recurrence in gynecologic cancer survivors.

Purpose of the Study:

  • To determine a more appropriate normal serum CA125 level for patients after successful surgical treatment of early-stage endometrial or cervical adenocarcinoma.
  • To evaluate if the existing normal CA125 threshold requires redefinition for post-treatment gynecologic cancer monitoring.

Main Methods:

  • Measured serum CA125 levels in 145 patients at least 1 year post-surgery for early-stage endometrial or cervical adenocarcinoma.
  • Ensured all patients were free of recurrent disease during a follow-up period averaging 4.3 years.

Related Experiment Videos

  • Analyzed 393 CA125 values to establish a new reference range.

    • Main Results:

    • 67% of CA125 values were below 10 U/ml, and 95% were 20 U/ml or less.
    • The median CA125 level in this patient cohort was 7.5 U/ml, with a mode of 7.1 U/ml.
    • No correlation was found between patient age and CA125 levels.

    Conclusions:

    • The established normal value of 35 U/ml for CA125 may not be suitable for post-treatment monitoring of gynecologic adenocarcinoma.
    • Data support redefining the upper limit of normal for serum CA125 to 20 U/ml in this patient population.
    • Further research is recommended to explore the clinical implications of this revised CA125 threshold.